Novo Nordisk A/S - Share repurchase programme Bagsværd, Denmark, 18 August 2014 - On 7 August 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January

2014.
Under the programme initiated 7 August 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 7 August 2014 to 28 October 2014.
Since the announcement as of 7 August 2014, the following transactions have been made under the programme:

Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement - -

7 August 2014 230,000 248.99 57,267,102

8 August 2014 210,000 244.58 51,362,220

11 August 2014 250,000 248.38 62,095,375

12 August 2014 250,000 246.35 61,587,225

13 August 2014 210,000 245.75 51,607,500

14 August 2014 210,000 246.79 51,825,837

15 August 2014 260,000 249.11 64,768,054

Accumulated under the programme 1,620,000 400,513,313


Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale
by Novo Nordisk of 93,975 B shares in the period from 7 August 2014 to 15 August

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 50 / 2014

Page 2 of 2

2014. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 36,267,039 B shares of DKK 0.20, corresponding to 1.4% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 15 August 2014, Novo Nordisk has repurchased a total of 33,357,995 B shares equal to a transaction value of DKK
8,105,031,812.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately

40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Katrine Sperling

+45 4442 6718

krsp@novonordisk.com

Investors:

Kasper Roseeuw Poulsen

+45 3079 4303

krop@novonordisk.com

Jannick Lindegaard Denholt

+45 3079 8519

jlis@novonordisk.com

Daniel Bohsen

+45 3079 6376

dabo@novonordisk.com

Frank Daniel Mersebach (US)

+1 609 235 8567

fdni@novonordisk.com

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 50 / 2014

distributed by